Role of CYP1B1 Retinoid in Congenital Glaucoma
Principal Investigator
Ivaylo Stoilov, MD
University of Connecticut Health Center
Farmington, CT, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2001 - March 31, 2003
Grant ID
G2001021
Summary
Some newborns and infants are affected by an especially severe form of glaucoma called Primary Congenital Glaucoma (PCG). PCG is caused by an abnormal development of the anterior chamber angle of the eye. In previous studies, Dr. Stoilov has found that this disease is caused by mutations in the gene for Cytochrome P4501B1 (CYPlBl). Humans have more than fifty different cytochrome P450 genes. They are responsible for the synthesis of various hormones and for detoxifying drugs, alcohol, and other chemicals. Based on the substrate specificity of CYPlBl, Dr. Stoilov hypothesizes that CYP1B1 affects a little-known retinoid signaling pathway operating during the later stages of eye development. Dr. Stoilov’s goal is to identify the enzymes involved in the CYPlBl pathway and study their expression during the development of the anterior chamber angle of the eye.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear